


-36-

CLAIMS

What is claimed is:

1. A compound of the formula:



and the pharmaceutically acceptable salts, hydrates, and prodrugs thereof, wherein;

- a) R^1 is represented by halogen, (C_1-C_2) alkyl, substituted with one or more halogens, or (C_1-C_2) alkoxy, substituted with one or more halogens,
- b) R^2 is represented by hydrogen or halogen,
- c) X^1 and X^2 are each independently represented by
 - i) (C_1-C_{12}) alkyl, optionally substituted,
 - ii) (C_2-C_{12}) alkenyl, optionally substituted,
 - iii) (C_2-C_{12}) alkynyl, optionally substituted,
 - iv) (C_3-C_{10}) cycloalkyl, optionally substituted,
 - v) (C_3-C_{10}) cycloalkyl (C_1-C_6) alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
 - vi) (C_6-C_{10}) aryl, optionally substituted,
 - vii) (C_6-C_{10}) aryl (C_1-C_6) alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
 - viii) $-(CH_2)_q-CH_2-ZH$, in which Z is S or O and q is an integer from 1-11,
 - ix) $-(CH_2)_n-Y-(CH_2)_p-CH_3$, in which Y is O or S, n is an integer from 1 to 4, and p is an integer from 1 to 4,
 - x) $-[CH_2]_m-C(O)R^3$, in which m is an integer selected from 1 to 8 and R^3 is represented by hydrogen, (C_1-C_{12}) alkyl, (C_6-C_{10}) aryl, or (C_6-C_{10}) aryl (C_1-C_6) alkyl, in which both the alkyl and aryl moieties may be optionally substituted,

-37-

- xi) $-\text{[CH}_2\text{]}_m\text{-C(O)-O-R}^4$, in which m is as defined above and R^4 is represented by hydrogen, $(\text{C}_1\text{-C}_{12})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, or $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, in which the alkyl and aryl moieties may be optionally substituted,
- 5 xii) $-\text{[CH}_2\text{]}_m\text{-C(O)-NR}^5\text{R}^6$ in which m is as described above, and R^5 and R^6 are each independently represented by hydrogen, $(\text{C}_1\text{-C}_{12})\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, or $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, in which the alkyl and aryl moieties may each be optionally substituted,
- 10 xvii) heteroaryl, optionally substituted,
- xviii) heteroaryl $(\text{C}_1\text{-C}_6)\text{alkyl}$, in which the heteroaryl and alkyl moieties may each be optionally substituted,
- xix) heterocyclic, optionally substituted, or,
- xx) heterocyclic $(\text{C}_1\text{-C}_6)\text{alkyl}$, in which the alkyl and
- 15 heterocyclic moieties may each be optionally substituted.

2. A compound according to claim 1 in which R^1 is represented by trifluomethyl.
3. A compound according to any one of claim s 1- or 2 in which said trifluoromethyl is located at the 4-position of the pyridine ring.
- 20 4. A compound according to anyone of claims 1-3 in which R^2 is hydrogen.
5. A compound according to anyone of claims 1-4 in which X^1 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ and X^2 is $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$.
6. A compound according to anyone of claims 1-5 in which X^1 and X^2 are each $(\text{C}_1\text{-C}_{12})\text{alkyl}$
- 25 7. A compound according to anyone of claims 1-6 in which X^1 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ and X^2 is $(\text{C}_3\text{-C}_{10})\text{cycloalkyl}(\text{C}_1\text{-C}_6)\text{alkyl}$.
8. A compound according to claim 1 selected from the group consisting of (R)-(+)-6-[Methyl-(1-Phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,

-38-

(R)-(+)-2-Chloro-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,
5 6-[methyl-(1-(4-fluorophenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
6-[methyl-(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
6-[butyl(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,
10 6-dipropylamino-4-trifluoromethyl-nicotinonitrile,
2-chloro-6-dimethylamino-4-trifluoromethyl-nicotinonitrile,
6-(hexyl-octyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-(sec-butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-[butyl-(2-hydroxy-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
15 6-(butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-(benzyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-(cyclohexyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-(cyclopropylmethyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,
6-(sec-butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile,
20 6-Dipropylamino-2-chloro-4-trifluoromethyl-nicotinonitrile,
6-(propyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile, and,
6-(Butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile.

9. Use of a compound according to anyone of Claims 1-8 as a medicine.
- 25 10. Use of a compound according to anyone of Claims 1-8 in the manufacture of a medicament for inhibiting activation of the androgen receptor.
11. A pharmaceutical composition comprising a compound according to any one of Claims 1-8 in admixture with 1, or more, pharmaceutically acceptable excipients.
- 30 12. A topical pharmaceutical formulation comprising a compound according to anyone of Claims 1-8 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

-39-

13. An article of manufacture comprising a compound according to any one of Claims 1-8 packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.

5

14. Use of a compound according to any one of claims 1-8 in the manufacture of a medicament for alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia.

10

15